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Abstract: Germline protein truncating variants (PTVs) in the FANCM gene have been associated
with a 2–4-fold increased breast cancer risk in case-control studies conducted in different European
populations. However, the distribution and the frequency of FANCM PTVs in Europe have never
been investigated. In the present study, we collected the data of 114 European female breast cancer
cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27
different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a
maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary,
p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*,
the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a
founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously
reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases.
Keywords: breast cancer predisposition; breast cancer risk factors; FANCM truncating variants;
mutation spectrum; PTVs
1. Introduction
FANCM, the Fanconi anemia (FA) complementation group M gene (OMIM609644), was originally
described as one of the members of the FA molecular pathway [1] that is primarily responsible for the
repair of the DNA inter-strand crosslinks through homologous recombination. FA is a recessive DNA
repair disease characterized by bone marrow failure, congenital malformations, chromosome fragility,
and cancer. Although FANCM is part of the core complex in the FA pathway, accumulating evidence
indicates that protein truncating variants (PTVs) in this gene are not causative of FA. Recently, eight
individuals who were not diagnosed with FA were found to harbor bi-allelic FANCM PTVs. Three
individuals developed early-onset cancers including lymphoblastic leukemia and squamous cancers [2].
In addition, five carriers of homozygous FANCM PTVs were identified among females diagnosed with
breast cancer, two of which were diagnosed with early onset disease [3]. Hence, it seems that bi-allelic
FANCM PTVs cause cancer predisposition with a greater risk for early onset development.
In the last years, results from case-control studies have indicated that mono-allelic FANCM PTVs
are breast cancer risk factors. The c.5101C > T (p.Gln1701*, rs147021911) is frequent in the Finnish
population with carrier frequency = 0.0162 versus 0.00168 in non-Finnish Europeans (NFE), as reported
in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/; [4]). In the Finnish population, p.Gln1701* was
found to be associated with breast cancer risk with an odds ratio (OR) of 1.86 and with greater effects
in familial cases, and for estrogen receptor-negative (ER-negative) and triple-negative breast cancer
(TNBC) subtypes [5]. This variant was later found to be also associated with breast cancer survival
and treatment outcome [6]. A second FANCM PTV, the c.5791C > T (p.Gly1906Alafs12*, rs144567652),
which is annotated and hereafter referred to as p.Arg1931*, showed association with breast cancer risk
in familial cases with OR = 3.93 [7]. This PTV was later found to also be associated with risk for TNBC
in Finnish cases with OR = 5.14 [8]. A sequencing analysis of the entire FANCM coding region showed
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an excess of a third common PTV, the c.1972C > T (p.Arg658*, rs368728266), in German breast cancer
cases versus controls, and confirmed that FANCM PTVs have a particularly high risk (OR = 3.75) for
TNBC [9]. We recently tested p.Arg658*, p.Gln1701*, and p.Arg1931* in 67,112 European breast cancer
cases and 53,766 controls. In these analyses, we observed that p.Arg658* was associated with increased
risk of ER-negative disease and TNBC with ORs of 2.44 and 3.79, respectively, and that p.Arg1931*
was associated with the risk of ER-negative breast cancer with an OR of 1.96 [10].
BRCA1, BRCA2, and PALB2 are established breast cancer predisposition genes conferring high risk
especially for ER-negative disease and TNBC. Similarly to other genes such as BARD1, RAD51D, BRIP1,
and RAD51C [11], FANCM is emerging as a breast cancer predisposing factor conferring a greater risk
specifically for these breast cancer subtypes. However, the spectrum of FANCM PTVs in Europe has
never been investigated. Through a project call addressed to ENIGMA consortium collaborators [12],
we collected data from European female breast cancer probands who were subjected to the sequencing
of the FANCM coding region, resulting as carriers of a FANCM PTV. This study describes the spectrum
of FANCM PTVs in this cohort of European breast cancer cases.
2. Results and Discussion
The 114 European breast cancer probands included in this study carried 27 different FANCM PTVs.
Four, namely c.1491dupA (p.Gln498Thrfs*7, rs797045117), p.Arg658*, p.Gln1701*, and p.Arg1931*,
were each identified in at least 8 probands and were classified as “common FANCM PTVs”. The
remaining 23 variants were unique or were found in not more than three probands and were classified
as “rare FANCM PTVs”. Additional data on common and rare FANCM PTVs were derived from
previously published studies based on FANCM sequencing of German breast cancer probands [9,13].
Altogether, these and our data allowed us to show the geographic distribution of the four common
PTVs and the rare PTVs combined in a cohort of breast cancer probands (Figure 1).
Of the 114 breast cancer probands, 86 (75.4%) carried one of the four common FANCM PTVs
(Table 1). Of these 86 probands, 8 (9.3%), carried the p.Gln498Thrfs*7, 13 (15.1%) the p.Arg658*, 38
(44.2%) the p.Gln1701*, and 27 (31.4%) carried the p.Arg1931*. We observed that the relative frequency
of the two most common PTVs, p.Gln1701* and p.Arg1931*, differ with respect to the country of
origin of carriers. The p.Gln1701* is the most common PTV in Northern Europe while it has a lower
relative frequency in Southern Europe. An opposite frequency gradient along the North–South axis
appeared to exist for p.Arg1931*, which is the most common PTV in Southern Europe but more rare
in Northern Europe. Consistently, in Central Europe, p.Gln1701* and p.Arg1931* are both common
with similar relative frequencies. The relative frequencies of the FANCM:p.Arg658*, the third most
common FANCM PTV, suggest that this variant has the highest frequency in Central Europe, is present
in Southern Europe, and seems to be absent or very rare in Scandinavia. The fourth common FANCM
PTV p.Gln498Thrfs*7 was identified in 6 of the 7 probands from Lithuania, suggesting it is a founder
variant from this specific geographic area (Table 1, Figure 1).
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Table 1. Eighty-six breast cancer probands who carry one of the four common FANCM PTVs.
Center/Study Country of Origin PTV Age at BCDiagnosis ER-Status
BC/OC Family
History
CZECANCA-Charles University, Prague Czech Republic p.Arg658* 53 ER-pos yes
CZECANCA-Charles University, Prague Czech Republic p.Arg658* 85 NA no
CZECANCA-Charles University, Prague Czech Republic p.Arg658* 35 NA yes
CZECANCA-Gennet, Prague Czech Republic p.Arg658* 66 ER-pos yes
CZECANCA-GHC, Prague Czech Republic p.Arg658* (#) 28 ER-pos yes
CZECANCA-Charles University, Prague Czech Republic p.Gln1701* 51 ER-neg yes
CZECANCA-Charles University, Prague Czech Republic p.Gln1701* 36 ER-pos no
CZECANCA-Gennet, Prague Czech Republic p.Gln1701* 40 ER-neg no
CZECANCA-Gennet, Prague Czech Republic p.Gln1701* 43 NA no
CZECANCA-GHC, Prague Czech Republic p.Gln1701* 45 ER-pos yes
CZECANCA-GHC, Prague Czech Republic p.Gln1701* 44 ER-pos no
CZECANCA-Charles University, Prague Czech Republic p.Arg1931* 41 ER-neg yes
CZECANCA-Charles University, Prague Czech Republic p.Arg1931* 46 ER-pos no
CZECANCA-Charles University, Prague Czech Republic p.Arg1931* 44 ER-pos yes
CZECANCA-GHC, Prague Czech Republic p.Arg1931* 63 NA no
Copenhagen Breast Cancer Study Denmark p.Gln1701* 58 ER-neg yes
Copenhagen Breast Cancer Study Denmark p.Gln1701* 50 ER-pos no
Copenhagen Breast Cancer Study Denmark p.Arg1931* 27 ER-pos yes
Helsinki Breast Cancer Study Finland p.Gln1701* 46 ER-pos yes
Helsinki Breast Cancer Study Finland p.Gln1701* 43 ER-pos yes
Helsinki Breast Cancer Study Finland p.Arg1931* 64 ER-pos yes
GENE SISters France p.Gln1701* 44 ER-pos yes
Institut Curie, Paris France p.Gln1701* 63 NA yes
GENE SISters France p.Arg1931* 54 ER-pos yes
GENE SISters France p.Arg1931* 39 ER-pos yes
GENE SISters France p.Arg1931* 65 ER-pos yes
GENE SISters France p.Arg1931* 45 ER-pos yes
GENE SISters France p.Arg1931* 43 NA yes
Institut Curie, Paris France p.Arg1931* 48 NA yes
National Center for Scientific Research-Demokritos, Athens Greece p.Arg658* 33 ER-neg no
National Center For Scientific Research-Demokritos, Athens Greece p.Gln1701* 61 ER-pos yes
National Center For Scientific Research-Demokritos, Athens Greece p.Arg1931* 63 ER-neg yes
National Center For Scientific Research-Demokritos, Athens Greece p.Arg1931* 42, 45 ER-pos no
Hungarian Breast and Ovarian Cancer Study Hungary p.Arg658* 44 ER-pos yes
Hungarian Breast and Ovarian Cancer Study Hungary p.Arg658* 35 ER-pos yes
Fondazione IRCCS-Istituto Nazionale dei Tumori, Milan Italy p.Arg1931* 49 NA yes
Istituto Scientifico Romagnolo per lo Studio e la Cura dei
Tumori, Meldola
Italy p.Arg1931* 32 ER-pos no
Vilnius University Hospital Santaros Klinikos Lithuania p.Gln498Thrfs*7 31 ER-neg no
Vilnius University Hospital Santaros Klinikos Lithuania p.Gln498Thrfs*7 35 ER-neg no
Vilnius University Hospital Santaros Klinikos Lithuania p.Gln498Thrfs*7 46 ER-pos no
Vilnius University Hospital Santaros Klinikos Lithuania p.Gln498Thrfs*7 39 ER-pos no
Vilnius University Hospital Santaros Klinikos Lithuania p.Gln498Thrfs*7 58 ER-pos yes
Vilnius University Hospital Santaros Klinikos Lithuania p.Gln498Thrfs*7 75 ER-pos no
Vilnius University Hospital Santaros Klinikos Lithuania p.Arg658* 39 ER-pos no
Macedonian Breast Cancer Study Macedonia p.Arg1931* 65 ER-neg no
Wroclaw Medical University, Wrocław Poland p.Gln498Thrfs*7 63 ER-neg no
Wroclaw Medical University, Wrocław Poland p.Gln498Thrfs*7 52 NA yes
Wroclaw Medical University, Wrocław Poland p.Arg658* 62 ER-pos yes
Portuguese Oncology Institute-Porto Breast Cancer Study Portugal p.Arg658* 29 NA yes
Fundación Pública Galega Medicina Xenómica, Santiago de
Compostela
Spain p.Arg658* 40 ER-neg no
Spanish National Cancer Research Centre, Madrid Spain p.Arg658* 38 ER-pos yes
Catalan Institute of Oncology, Barcelona Spain p.Arg1931* 48 ER-pos yes
Catalan Institute of Oncology, Barcelona Spain p.Arg1931* 55 ER-pos yes
Spanish National Cancer Research Centre, Madrid Spain p.Arg1931* 47 NA yes
Swedish Breast Cancer Study Sweden p.Gln1701* 34 ER-neg yes
Swedish Breast Cancer Study Sweden p.Gln1701* 58 ER-neg yes
Swedish Breast Cancer Study Sweden p.Gln1701* 21 ER-neg yes
Swedish Breast Cancer Study Sweden p.Gln1701* 71 ER-neg yes
Swedish Breast Cancer Study Sweden p.Gln1701* 71 ER-neg yes
Swedish Breast Cancer Study Sweden p.Gln1701* 57 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 37 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 68 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 43 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 54 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 56 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 48 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 27 ER-pos no
Swedish Breast Cancer Study Sweden p.Gln1701* 42 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 60 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 44 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 57 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 32 ER-pos yes
Swedish Breast Cancer Study Sweden p.Gln1701* 46 NA yes
Swedish Breast Cancer Study Sweden p.Gln1701* 49 NA yes
Swedish Breast Cancer Study Sweden p.Gln1701* 36 NA no
Swedish Breast Cancer Study Sweden p.Gln1701* 46 NA yes
Swedish Breast Cancer Study Sweden p.Gln1701* 39 NA no
Swedish Breast Cancer Study Sweden p.Gln1701* 28 NA yes
Swedish Breast Cancer Study Sweden p.Gln1701* 47 NA yes
Swedish Breast Cancer Study Sweden p.Arg1931* 36 ER-neg yes
Swedish Breast Cancer Study Sweden p.Arg1931* 47 ER-neg no
Swedish Breast Cancer Study Sweden p.Arg1931* 52 ER-pos yes
Swedish Breast Cancer Study Sweden p.Arg1931* 55 ER-pos yes
Swedish Breast Cancer Study Sweden p.Arg1931* 36 ER-pos no
Swedish Breast Cancer Study Sweden p.Arg1931* 39 NA yes
Swedish Breast Cancer Study Sweden p.Arg1931* 56 NA yes
PTV, protein truncating variant; BC, breast cancer; OC, ovarian cancer; ER, estrogen receptor; pos, positive; neg,
negative; NA, not available. (#) This individual also carries the rare FANCM: c.3088C > T (p.Arg1030*) PTV and is
also included in Table 2.
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Table 2. Twenty-nine breast cancer probands who carry one of the 23 rare FANCM PTVs.
Center/Study Country of Origin PTV Annotated inDatabases
Age at BC
Diagnosis ER-Status
BC/OC Family
History
CZECANCA-AGEL, Novy Jicin Czech Republic c.1798C > T; p.Gln600* no 37 ER-pos yes
CZECANCA-Charles University, Prague Czech Republic c.3898G > T; p.Glu1300* no 37 ER-pos no
CZECANCA-Charles University, Prague Czech Republic c.3979_3980delCA;
p.Gln1327Valfs*16
LOVD, gnomAD 50 ER-pos yes
CZECANCA-Gennet, Prague Czech Republic c.2260C > T; p.Arg754* gnomAD 51 ER-neg no
CZECANCA-Gennet, Prague Czech Republic c.2260C > T; p.Arg754* gnomAD 34 ER-neg no
CZECANCA-GHC, Prague Czech Republic c.3088C > T; p.Arg1030* (#) no 28 ER-pos yes
Copenhagen Breast Cancer Study Denmark c.3745_3748del;
p.Thr1249Glnfs*7
no 50 ER-pos NA
Helsinki Breast Cancer Study Finland c.4021_4022del no 39 ER-pos yes
GENE SISters France c.1432C > T; p.Arg478* no 48 NA yes
GENE SISters France c.3745dupA; p.His1248fs no 63 NA yes
Institut Curie, Paris France c.1868delA; p.Arg624Glufs*46 no 56 ER-neg yes
Institut Curie, Paris France c.2260C > T; p.Arg754* gnomAD 43 ER-neg yes
Institut Curie, Paris France c.2590delG; p.Asp864Ilefs*12 no 64 ER-neg yes
Institut Curie, Paris France c.4930C > T; p.Arg1644* gnomAD 46 NA yes
Institut Curie, Paris France c.5363delCTAG;
p.Ser1788Leufs*15
no 43 ER-neg no
National Center For Scientific
Research-Demokritos, Athens
Greece c.4843A > T; p.Lys1615* LOVD 33 NA yes
National Center For Scientific
Research-Demokritos, Athens
Greece c.5314_5315delTG; p.Cys1772* LOVD, gnomAD 47 ER-pos yes
Fondazione IRCCS-Istituto Nazionale dei
Tumori, Milan
Italy c.2354T > G; p.Leu785* no 35 NA no
Macedonian Breast Cancer Study Macedonia c.5048_5052delAAAGA;
p.Lys1683Argfs*3
gnomAD 32 ER-neg no
Portuguese Oncology Institute-Porto Breast
Cancer Study
Portugal c.2320G > T; p.Glu774* no 42 ER-neg yes
Portuguese Oncology Institute-Porto Breast
Cancer Study
Portugal c.5766_5769del;
p.Thr1923Profs*2
no 43 ER-neg yes
Catalan Institute of Oncology, Barcelona Spain c.624_625delAA; p.Ile208fs no 23 NA no
Catalan Institute of Oncology, Barcelona Spain c.1303C > T; p.Gln435* no 39 ER-pos yes
Catalan Institute of Oncology, Barcelona Spain c.5766_5769del;
p.Thr1923Profs*2
no 31 ER-pos no
Fundación Pública Galega Medicina
Xenómica, Santiago de Compostela
Spain c.2320G > T; p.Glu774* no 57 ER-neg yes
Fundación Pública Galega Medicina
Xenómica, Santiago de Compostela
Spain c.2586_2589delAAAA;
p.Lys863Ilefs*12
ClinVar, LOVD,
gnomAD
49 NA yes
Spanish National Cancer Research Centre,
Madrid
Spain c.1196C > G; p.Ser399* ClinVar 66 NA yes
Spanish National Cancer Research Centre,
Madrid
Spain c.2320G > T; p.Glu774* no 40, 65 ER-pos yes
Spanish National Cancer Research Centre,
Madrid
Spain c.4843A > T; p.Lys1615* LOVD 41 NA yes
PTV, protein truncating variant; BC, breast cancer; OC, ovarian cancer; ER, estrogen receptor; pos, positive; neg,
negative; NA, not available. (#) This individual also carries the common PTV, p.Arg658*, and is also included in Table 1.
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The high relative frequency of FANCM:p.Gln498Thrfs*7 observed in Lithuania could indicate a
founder effect in this relatively homogenous Baltic population. Similarly, haplotype analyses previously
conducted in this population found a strong founder effect for several recurrent pathogenic variants in
the high-risk predisposition genes BRCA1 and BRCA2 [14,15]. Calculations from haplotype analysis
and paleo-demographic data indicate that a bottleneck phenomenon occurring approximately in the
4th–5th century AD in the Lithuanian region could have contributed to decreased genetic diversity
and subsequent expansion of specific alleles [14].
We compared the geographic distribution of the four common PTVs observed in our study cohort
with that reported in the gnomAD database v2.1.1 [4]. In gnomAD, 630 European individuals carried
one of the p.Gln498Thrfs*7, p.Arg658*, p.Gln1701* or p.Arg1931* PTVs with relative proportions of
3.2% (20/630), 3.3% (21/630), 54.0% (340/630), and 39.5% (249/630), respectively. About half of the
p.Gln498Thrfs*7 gnomAD carriers (9/20) were from Estonia, confirming that this variant has a specific
origin in the Baltic countries. In gnomAD, p.Arg658* was prevalently found in NFE with the higher
frequency of the carries (8/21) found in North-western Europeans and only one carrier found among
Southern Europeans, which is similar to what we observed. Having being found in 340 gnomAD
individuals, FANCM:p.Gln1701* is by far the most common PTV in Europe. As mentioned before,
p.Gln1701* was particularly frequent in Finland and was observed more frequently in North-western
than Southern Europeans, which is consistent with our data. FANCM:p.Arg1931* was the second most
common FANCM PTV in Europe and the most common FANCM PTV in Southern Europeans in the
gnomAD dataset. However, this variant was reported to be the most common also in North-western
Europeans, not confirming the South–North frequency gradient observed in our cohort.
Of the 114 breast cancer probands, 29 (25.4%) carried one of the 23 rare FANCM PTVs (Table 2).
Interestingly, a proband from the Czech Republic was a bi-allelic carrier of FANCM PTVs having
inherited the rare p.Arg1030* variant from the mother, and the common p.Arg658* variant from the
paternal side of the family (Tables 1 and 2). This carrier was diagnosed with breast cancer at a young
age (28 years), which is consistent with published data showing that females with bi-allelic FANCM
PTV may develop early onset disease [3]. Eight of the 23 rare PTVs were annotated in the public
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), LOVD (https://www.lovd.nl/), or gnomAD databases
and 15 were novel. Of the 23 rare PTVs, 19 were unique; two, p.Arg754* and p.Glu774*, were found
in three probands; and two, p.Lys1615* and p.Thr1923Profs*2, in two probands. Given these low
frequencies, we could not speculate on the origins or the geographic distribution of any of the rare
FANCM PTVs. Considering the numbers of carriers of common PTVs and rare PTVs in each country,
we observed that in Spain and France, there was an apparent excess of carriers of rare PTVs. On the
contrary, in Sweden and Lithuania, no carriers of rare PTVs were found (Figure 1).
3. Materials and Methods
The individuals included in our analysis were contributed by ENIGMA consortium
collaborators [12] interested in studying the effect/role of FANCM on breast cancer predisposition.
They were originally ascertained at several Centers or National Studies and considered eligible for
mutation sequencing analysis of breast and/or ovarian cancer predisposing genes in the frame of
diagnostic or research purposes. In general, the ascertainment criteria for mutation testing were based
on the presence of family history for breast or ovarian cancer, and on the early onset or specific clinical
subtype of breast cancer. In the present study, we included 114 probands who received (i) a diagnosis
of breast cancer, (ii) tested negative for BRCA1 or BRCA2 pathogenic variants, (iii) underwent complete
sequencing of the FANCM coding region, resulting as a carrier of a PTV. Unfortunately, it was not
possible to retrieve the number of probands that were originally subjected to mutation sequencing
analysis at each participating Center or National Study. The 114 carriers of FANCM PTVs were
ascertained in 20 Centers or National Studies from 13 European countries (Table S1) including Czech
Republic (20, 17.5%), Denmark (4, 3.5%), Finland (4, 3.5%), France (15, 13.2%), Greece (6, 5.3%), Hungary
(2, 1.8%), Italy (3, 2.6%), Lithuania (7, 6.1%), Macedonia (2, 1.8%), Poland (3, 2.6%), Portugal (3, 2.6%),
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Spain (15, 11.4%), and Sweden (32, 28.1%). Some of these FANCM PTVs carriers were described in
studies previously published, as indicated (Table S1). Of the 114 probands, 58 (50.9%) were ER-positive,
27 (23.7%) were ER-negative, and 80 (70.2%) had a positive family history of breast or ovarian cancer.
The mean age at breast cancer diagnosis was 46.7 years (min = 21, max = 85). All the 114 probands
provided written informed consent for their data to be used for research purposes or specifically agreed
to be tested for new variants in potential breast cancer associated genes. The participation of all the
Centers or National Studies in the present work (Table S1) was approved by their ethic committees.
Specifically, these are the Ethics Committee of the General University Hospital in Prague (Approval
code 87/14); Ethics Committee of Carlos III Institute of Health in Madrid (CEI PI 06_2013-v2); by the
appropriate Advisory Committee on the Treatment of Health Research Information (ComitéConsultatif
de Protection des Personnes dans la Recherche Biomédicale (CCPPRB) Ile-de-France III) and by the
National Data Protection authority; Ethics Committee of Fondazione IRCCS Istituto Nazionale dei
Tumori in Milan (INT 7/15); Ethics Committee of the Capital Region of Denmark (H-4-2010-050); Ethics
Committee of Hospital District of Helsinki and Uusimaa (HUS/1597/2016); Ethical Sub-Committee
on Medicine, Pharmacy, Veterinary and Dental Medicine, Macedonian Academy of Sciences and
Arts (09-1047/1 from 20/04/2016); IPO (Instituto Português de Oncologia) Porto institutional review
board (nr. 219-019); Comité Territorial de Ética de la Investigación de Santiago -Lugo, Conselleria
de Sanidade, Xunta de Galicia (2018/200); Ethics Committee of the Area Vasta Romagna e I.R.S.T
(CEAV, 1727/2012 I.5/43); Provincial Ethics Committee (209/16) and the Modena Hospital (3387); Ethics
Committee of University of Rzeszow, Poland (resolution no. 9/06/2015), University of Melbourne
Human Research Ethics Committee, Melbourne, Australia; National Scientific and Ethics Committee
(ETT-TUKEB), 20998-0/2010-1018EKU (845/PI/010); IDIBELL (Institut d’Investigacio Biomedica de
Bellvitge, Barcelona) Ethics Committee PR278/19; Lithuanian Bioethics Committee (LT-HCCA-003
protocol), Vilnius Regional Ethics Committee (Nr. 58200-12-27(1-61); Ethics Committee of Lund,
Sweden (Dnr 2011/349 and 2011/652); Bioethics Committee of NSCR (National Centre of Scientific
Research) Demokritos (BcncSrD-240/eH∆/11.3, updated on 29 June 2015).
4. Conclusions
We described the geographic distribution and relative prevalence of 27 different FANCM PTVs
detected in 114 female European breast cancer probands with no pathogenic variants in BRCA1 or
BRCA2 genes. As far as we know, this is the largest available collection of breast cancer probands
carrying FANCM PTVs. In our study-cohort, we found that the FANCM: p.Gln1701* had high relative
frequency in Northern Europe and low relative frequency in Southern Europe, whereas p.Arg1931*
was the most common PTV in Southern Europe and less common in Northern Europe. The p.Arg658*
had higher frequency in Central Europe, while p.Gln498Thrfs*7 is probably a founder variant from
Lithuania. Fifteen of the 27 PTVs described are novel, including one found in three probands, and one
found in two probands. Further data are warranted to provide an extensive spectrum of FANCM PTVs
in Europe.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/2/292/s1,
Table S1: Center or Study contributing the 114 FANCM PTV probands. Some of these probands were previously
described as indicated; sequencing details are provided.
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